A new clutch of biotech blue-chippers joins Obsidian’s quest to craft next-gen drugs with an ‘on’ switch

The brainchild of serial biotech entrepreneur Michael Gilman, Obsidian is hoping to bring something new to the party with “on-switch” technology for a range of potential drug applications. Obsidian now has a new treasure chest to play with — and an IPO feels only a fingertip away.

Obsidian closed a...

Click to view original post